Abstract

--- - Plain language summaryCorneal neovascularization is an eye disease that affects over 1 million people every year and can lead to blindness. It is caused by inflammation and the unwanted formation of blood vessels in the eye. Current treatments for this disease are not fully effective. Atorvastatin (ATV) is one drug that has been partially successful at treating corneal neovascularization, but it does not stay in the eye long enough and does not mix well with the water-based environment of the eye. To overcome this, ATV was combined with three specially designed nanocarriers. These nanocarriers were peptides, short stretches of protein. They were designed to be amphiphilic, meaning that one section is hydrophilic (literally meaning 'water loving') and one section is hydrophobic ('water hating'). These peptide nanocarriers allowed ATV to stay in the water-based environment of the eye longer. The peptide with the most hydrophobic chains (qC(16)-Tat(47-57)) was able to carry more ATV than the other peptides and produced particles of a desired shape. ATV-qC(16)-Tat(47-57) nanocarriers were found to release slowly. These nanocarriers were also found to prevent the development of new blood vessels on a membrane in a hen's egg used to mimic the eye. There was also no sign of irritation on this membrane or in the eyes of New Zealand rabbits. These results show ATV-qC(16)-Tat(47-57) has a prolonged therapeutic effect, prevents the formation of new blood vessels and is tolerated in the eye. ATV-qC(16)-Tat(47-57) is therefore potentially a more effective alternative to ATV treatment alone. - "Background: Corneal neovascularization is a sight-threatening disease. It can be treated using antiangiogenic and anti-inflammatory compounds. Therefore, atorvastatin (ATV) constitutes a suitable candidate to be administered topically. To attain suitable efficacy, ATV can be encapsulated into custom-developed nanocarriers such as peptide amphiphiles. Methods: Three peptide amphiphiles bearing one, two or four C-16-alkyl groups (mC(16)-Tat(47-57), dC(16)-Tat(47-57) and qC(16)-Tat(47-57)) were synthesized, characterized and loaded with ATV. Drug release and ocular tolerance were assessed as well as anti-inflammatory and antiangiogenic properties. Results: ATV-qC(16)-Tat(47-57) showed higher encapsulation efficiency than mC(16)-Tat(47-57) and dC(16)-Tat(47-57) and more defined nanostructures. ATV-qC(16)-Tat(47-57) showed ATV prolonged release with suitable ocular tolerance. Moreover, ATV-qC(16)-Tat(47-57) was antiangiogenic and prevented ocular inflammation. Conclusion: ATV-qC(16)-Tat(47-57) constitutes a promising topical medication against corneal neovascularization." - Tweetable abstractA new peptide able to self-assemble encapsulating atorvastatin has been custom synthesized. It was demonstrated to deliver atorvastatin in a prolonged manner and to be therapeutically effective against corneal neovascularization.